NovoCure (NASDAQ: NVCR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.33) by 60.61 percent. This is a 63.89 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $183.584 million which beat the analyst consensus estimate of $172.437 million by 6.46 percent. This is a 15.60 percent increase over sales of $158.805 million the same period last year.